Novel Biomarkers in Assessment of Interstitial Lung Disease Associated With Rheumatoid Arthritis Patients

NCT07003451 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-08-28

No results posted yet for this study

Summary

\- Assess Krebs von den Lungen-6 (KL-6) and Calprotectin as novel biomarkers for diagnosis of ILD among Rheumatoid arthritis patients

Conditions

Interventions

DIAGNOSTIC_TEST

Calprotectin Level

Measurement of calprotectin level to presence and severity of ILD asessed via Warrick's score

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • waleed gamal elddin, ass. prof · Assiut University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2026-01-01
Completion
2026-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07003451 on ClinicalTrials.gov